Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00395746 | Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes | PHASE3 | COMPLETED | 264 | — | — | Oct 1, 2006 | May 1, 2008 | Mar 8, 2017 | 1 | Japan |
| Arm | Type | Description |
|---|---|---|
| 0.6 mg + SU | EXPERIMENTAL | Liraglutide 0.6 mg + sulphonylurea |
| 0.9 mg + SU | EXPERIMENTAL | Liraglutide 0.9 mg + sulphonylurea |
| SU Mono - 1 | PLACEBO_COMPARATOR | Liraglutide placebo 0.6 mg + sulphonylurea |
| SU Mono - 2 | PLACEBO_COMPARATOR | Liraglutide placebo 0.9 mg + sulphonylurea |
| Name | Type | Description |
|---|---|---|
| sulfonylurea | DRUG | SU agent |
| liraglutide | DRUG | Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily. |
Inclusion Criteria: * Type 2 diabetes * Diet/exercise therapy with sulfonylurea (SU) for at least eight weeks * HbA1c greater than or equal to 7.0% and less than 10.0% * BMI less than 35 kg/m2 Exclusion Criteria: * Treatment with insulin within the last 12 weeks * Treatment with any drug that cou...